A Phase 2 interventional study of Shared Decision-Making Toolkit in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to female participants aged 80 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute — 15 open to participants now, 43 under way, none of them phase 3. Breast Neoplasms · Dana-Farber Cancer Institute.
Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 13th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2025, is one of 56 in phase 2, reaches primary completion later than 27 of the 42 other live ones, and was the 136th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →15 of the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute are open now, in 2 countries. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18–49 · Women only
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 80 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 60 · Phase 3 2
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 364 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 50 across the 132 interventional studies, 112 across the 10 observational. Of the 95 that completed or were terminated, 45 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
12 of the studies in Breast Neoplasms by Dana-Farber Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04434040Dana-Farber Cancer InstituteAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | 2026-12-30 |
| NCT05327452Dana-Farber Cancer InstituteTesting Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study | 2026-12-31 |
| NCT07482384Dana-Farber Cancer InstituteSupporting Health Including Endocrine Treatment for Long Duration | 2027-01 |
| NCT04379414Dana-Farber Cancer InstituteYES Study - Newly Diagnosed/Metastatic Intervention | 2027-03-01 |
| NCT04468061Dana-Farber Cancer InstituteSacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | 2027-04-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
A participant will be placed into one of two groups: Group A: Usual Care vs. Group B: SDM Toolkit according to the randomized placement of the assigned study clinician.
Study procedures include questionnaires and option interviews with study staff.
Participation in this research study is expected to last about 2 years.
It is expected about 52 clinicians and 312 participants will take part in this research study.
The National Institute on Aging is providing funding for this research study
Participant Inclusion Criteria:
Has had mammogram screening/surveillance within the last 24 months
-≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)
Most recent mammogram report for the potential participant did not recommend additional diagnostic work-up or close interval follow-up imaging
Participant Exclusion Criteria:
Clinician Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled participants will complete: * Year 1 standard of care visit with clinician followed by post-visit survey * Optional semi-structured interview with study staff * Year 2 standard of care visit with clinician followed by post-visit survey * Optional semi-structured interview with study staff * End of study survey
Behavioral: Shared Decision-Making Toolkit
Enrolled participants will continue with standard care practices without the SDM toolkit and will complete: * Year 1 standard of care visit with clinician followed by post-visit survey * Year 2 standard of care visit with clinician followed by post-visit survey * Optional semi-structured interview with study staff
The SDM toolkit is designed to support discussions on the continuation of surveillance mammography. It provides evidence-based guidelines, communication strategies, and education materials to aid in personalized decision-making.
Also known as: SDM Toolkit
Mammography Rate
Mammography Rate is defined as the proportion of participants that undergo mammography by 2 years post-enrollment.
Time frame: Assessed at 2 years post-enrollment.
Mammography Count
Mammography Count is defined as the count of all mammograms each participant underwent during study follow-up.
Time frame: Assessed at 2 years post-enrollment.
Participant Knowledge Score
Participant Knowledge Score will be defined as the proportion of correct knowledge questions (range: 0 to 1).
Time frame: Annually through 2 years of follow-up post-enrollment.
Participant Decisional Quality Score
Participant Decisional Quality Score will be defined as the sum of response scores (range of 0-4), with each individual response scored 0 or 1. Higher scores indicate higher decisional quality.
Time frame: Annually through 2 years of follow-up post-enrollment.
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 24 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →